Ghent, BELGIUM – 17 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, ...

March 13, 2003 — Transjugular intrahepatic portosystemic shunts (TIPS) plus medical therapy is better than medical therapy alone in controlling ascites, but not in improving survival, hospitalization ...

Ghent, Belgium – 23 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump ® system in patients with ascites caused by cancer (malignant ascites). The alfapump ® system was ...

Sequana Medical AG ("Sequana Medical"), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the ...

Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without ...

There are many times when we visit a doctor for a common ache or pain, and he/she uses big and scary sounding words to tell us what we are suffering from. But that jargon often has a common and simple ...

Ascites usually occurs when the liver stops working properly, leading to a build up of fluid in the abdominal area. A doctor may diagnose ascites when more than 25 milliliters (mL) of fluid builds up ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump® is the first US approved active implantable medical device ...